Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. c...

https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-13-05-00-00-2880074

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately c...

Editor’s note: This story has been updated to correct an error in the price action of Charter Communications stock.

Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront pay...

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined c...

Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalt...

Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+...

- Bloomberg

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatm...